Literature DB >> 2405382

Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.

M Bryant1, L Ratner.   

Abstract

Covalent linkage of myristic acid to the N-terminal glycine residue of Pr55gag, the precursor of the major structural proteins of human immunodeficiency virus 1 (HIV-1), facilitates an essential step in virus assembly and propagation. Substitution of the myristoyl-acceptor glycine with alanine, in a functional clone of HIV-1, eliminates virus replication. Complementation of this defect, in trans, restores infectious particle production. The nonmyristoylated (myr-) gag precursor accumulates in infected cells and is not processed into the mature capsid components of the intact virion. However, myr- Pr55gag can be processed by purified HIV protease in vitro, demonstrating that the myristoyl moiety is not required for cleavage by the protease. Myristoylation of Pr55gag is not necessary for localization but is required for stable membrane association and assembly of HIV-1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2405382      PMCID: PMC53297          DOI: 10.1073/pnas.87.2.523

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  Fatty acid binding to vesicular stomatitis virus glycoprotein: a new type of post-translational modification of the viral glycoprotein.

Authors:  M F Schmidt; M J Schlesinger
Journal:  Cell       Date:  1979-08       Impact factor: 41.582

2.  Relation of fatty acid attachment to the translation and maturation of vesicular stomatitis and Sindbis virus membrane glycoproteins.

Authors:  M F Schmidt; M J Schlesinger
Journal:  J Biol Chem       Date:  1980-04-25       Impact factor: 5.157

Review 3.  The biology and enzymology of eukaryotic protein acylation.

Authors:  D A Towler; J I Gordon; S P Adams; L Glaser
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

4.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Myristyl amino-terminal acylation of murine retrovirus proteins: an unusual post-translational proteins modification.

Authors:  L E Henderson; H C Krutzsch; S Oroszlan
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

7.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

Review 8.  Fatty acid binding: a new kind of posttranslational modification of membrane proteins.

Authors:  M F Schmidt
Journal:  Curr Top Microbiol Immunol       Date:  1983       Impact factor: 4.291

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  329 in total

1.  Membrane association induces a conformational change in the Ebola virus matrix protein.

Authors:  S Scianimanico; G Schoehn; J Timmins; R H Ruigrok; H D Klenk; W Weissenhorn
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

2.  Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus.

Authors:  A Ono; E O Freed
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.

Authors:  R E Kiernan; A Ono; E O Freed
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Activation of the Mason-Pfizer monkey virus protease within immature capsids in vitro.

Authors:  S D Parker; E Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

5.  Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.

Authors:  S S Chen; S F Lee; C T Wang
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging.

Authors:  L Hermida-Matsumoto; M D Resh
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera.

Authors:  J B Bowzard; R J Visalli; C B Wilson; J S Loomis; E M Callahan; R J Courtney; J W Wills
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Human cytomegalovirus UL99-encoded pp28 is required for the cytoplasmic envelopment of tegument-associated capsids.

Authors:  Maria C Silva; Qian-Chun Yu; Lynn Enquist; Thomas Shenk
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Positive and negative modulation of virus infectivity and envelope glycoprotein incorporation into virions by amino acid substitutions at the N terminus of the simian immunodeficiency virus matrix protein.

Authors:  Julieta M Manrique; Cristina C P Celma; Eric Hunter; José L Affranchino; Silvia A González
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Assembly properties of human immunodeficiency virus type 1 Gag-leucine zipper chimeras: implications for retrovirus assembly.

Authors:  Rachael M Crist; Siddhartha A K Datta; Andrew G Stephen; Ferri Soheilian; Jane Mirro; Robert J Fisher; Kunio Nagashima; Alan Rein
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.